Afficher la notice abrégée

dc.contributor.authorSequera, Celia
dc.contributor.authorBragado, Paloma
dc.contributor.authorManzano, Sara
dc.contributor.authorArechederra, Maria
dc.contributor.authorRichelme, Sylvie
dc.contributor.authorGutiérrez-Uzquiza, Alvaro
dc.contributor.authorSánchez, Aránzazu
dc.contributor.authorMaina, Flavio
dc.contributor.authorGuerrero Arroyo, María Carmen 
dc.contributor.authorPorras, Almudena
dc.date.accessioned2022-03-01T10:31:26Z
dc.date.available2022-03-01T10:31:26Z
dc.date.issued2020-08-14
dc.identifier.citationSequera C, Bragado P, Manzano S, Arechederra M, Richelme S, Gutiérrez-Uzquiza A et al. C3G Is Upregulated in Hepatocarcinoma, Contributing to Tumor Growth and Progression and to HGF/MET Pathway Activation. Cancers. 2020;12(8):2282.es_ES
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10366/148931
dc.description.abstract[EN]The complexity of hepatocellular carcinoma (HCC) challenges the identification of disease-relevant signals. C3G, a guanine nucleotide exchange factor for Rap and other Ras proteins, plays a dual role in cancer acting as either a tumor suppressor or promoter depending on tumor type and stage. The potential relevance of C3G upregulation in HCC patients suggested by database analysis remains unknown. We have explored C3G function in HCC and the underlying mechanisms using public patient data and in vitro and in vivo human and mouse HCC models. We found that C3G is highly expressed in progenitor cells and neonatal hepatocytes, whilst being down-regulated in adult hepatocytes and re-expressed in human HCC patients, mouse HCC models and HCC cell lines. Moreover, high C3G mRNA levels correlate with tumor progression and a lower patient survival rate. C3G expression appears to be tightly modulated within the HCC program, influencing distinct cell biological properties. Hence, high C3G expression levels are necessary for cell tumorigenic properties, as illustrated by reduced colony formation in anchorage-dependent and -independent growth assays induced by permanent C3G silencing using shRNAs. Additionally, we demonstrate that C3G down-regulation interferes with primary HCC tumor formation in xenograft assays, increasing apoptosis and decreasing proliferation. In vitro assays also revealed that C3G down-regulation enhances the pro-migratory, invasive and metastatic properties of HCC cells through an epithelial-mesenchymal switch that favors the acquisition of a more mesenchymal phenotype. Consistently, a low C3G expression in HCC cells correlates with lung metastasis formation in mice. However, the subsequent restoration of C3G levels is associated with metastatic growth. Mechanistically, C3G down-regulation severely impairs HGF/MET signaling activation in HCC cells. Collectively, our results indicate that C3G is a key player in HCC. C3G promotes tumor growth and progression, and the modulation of its levels is essential to ensure distinct biological features of HCC cells throughout the oncogenic program. Furthermore, C3G requirement for HGF/MET signaling full activation provides mechanistic data on how it works, pointing out the relevance of assessing whether high C3G levels could identify HCC responders to MET inhibitors.es_ES
dc.format.mimetypeapplication/pdf
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectC3Ges_ES
dc.subjectHepatocarcinomaes_ES
dc.subjectCanceres_ES
dc.subjectMETes_ES
dc.subjectCell signalinges_ES
dc.subject.meshCarcinoma, Hepatocellular *
dc.titleC3G is upregulated in hepatocarcinoma, contributing to tumor growth and progression and to HGF/MET pathway activationes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3390/cancers12082282es_ES
dc.subject.unesco3207.13 Oncologíaes_ES
dc.subject.unesco2415 Biología Moleculares_ES
dc.subject.unesco3207.08 Hematologíaes_ES
dc.identifier.doi10.3390/cancers12082282
dc.relation.projectIDMarie Curiees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid32823931
dc.journal.titleCancerses_ES
dc.volume.number12es_ES
dc.issue.number8es_ES
dc.page.initial2282es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decscarcinoma hepatocelular *


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional